Fig 5. Distribution of chemokine receptor CCR4⁺CCR6^–, CCR4^–CCR6⁺ and CCR4⁺CCR6⁺ subpopulations of CD4⁺ T lymphocytes.

(A) PBMCs were stained with anti-CD4 PE-cy7, anti-CCR4 PE, anti-CCR6 APC and anti-IL-17 FITC. CD4+ T cells were gated for further analysis. (B) The proportion (%) of CCR4⁺CCR6^–/CD4⁺ T cells (C) CCR4^–CCR6⁺/CD4⁺ T cells (D) CCR4⁺CCR6⁺/CD4⁺ T cells in each patient group. (E) After surface staining with anti-CD4, CCR4 and CCR6 mAbs, analysis of IL-17 in CD4⁺ T cell subsets by intracellular flow cytometry was done. (F) The proportion (%) of IL-17⁺/CCR4⁺CCR6⁺CD4⁺ T cells in each patient group. * P<0.05 for each comparison. LTS, long term stable; CAD, chronic allograft dysfunction; ES, early stable; ESRD, end stage renal disease; HC, healthy control.